Loading stock data…
Inogen, Inc (INGN)
$6.93-0.01 (-0.14%)
Market ClosedLast close Jun 29
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inogen, Inc. in the Healthcare sector is trading at $6.93 with a market capitalization of $162M. Wall Street consensus targets $12.67 (3 analysts), implying a +82.8% move over the next 12 months. The stock is currently 24% below its 52-week high of $9.13, remaining 0.6% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +82.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $85.11M↑ | $81.72M↓ | $92.39M↑ | $92.28M↑ | $82.28M |
| Gross Profit | $37.86M↑ | $35.24M↓ | $41.32M | $41.34M↑ | $36.37M |
| Operating Income | -$9.34M↓ | -$9.31M↓ | -$7.12M↓ | -$6.13M↑ | -$7.66M |
| Net Income | -$8.32M↓ | -$7.13M↓ | -$5.29M↓ | -$4.15M↑ | -$6.17M |
Peer Comparison
JNJUNHPFE
Fundamentals
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen thera...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$161.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.61%
Volume
Today's trading volume
147,251
Recent News
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC strength, expanding respiratory portfolio and international momentum support growth, though U.S. revenue pressure remains a key risk.
How The Inogen (INGN) Story Is Shifting With New Targets And Execution Questions
The latest analyst update trims Inogen’s fair value estimate from $13.00 to about $12.67 per share, a reduction of roughly 2.6%. Analysts are using this adjustment alongside the recent bullish initiation to refresh their models, weigh execution risks, and reassess how comfortable they are with the stock at current levels. As you read on, you will see how these shifting targets shape the evolving narrative around Inogen and what to watch next. Stay updated as the Fair Value for Inogen shifts...
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen posts higher Q1 revenues and improved gross margin as international portable oxygen demand offsets weaker U.S. sales.
Inogen, Inc. Q1 2026 Earnings Call Summary
Moby summary of Inogen, Inc.'s Q1 2026 earnings call
Inogen Q1 Earnings Call Highlights
Inogen (NASDAQ:INGN) reported first-quarter 2026 revenue of $85.1 million, up 3.4% year over year and “ahead of our expectations,” President and CEO Kevin Smith said on the company’s earnings call. Management pointed to continued strength internationally, partially offset by ongoing pressure in U.S.